ASH 2025 preview – Kelonia gets a late-breaking coup
An in vivo Car-T produced a 100% response rate – in three patients.
ASH 2025 preview – another degrader fight
Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
ASH 2025 preview – a new menin battleground
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
ASH 2025 preview – multiple myeloma focus
Arcellx and AstraZeneca take centre stage.
Epkinly gets a second-line follicular nod
And AbbVie and Genmab scoop their ASH presentation with new data.
Ziihera bags a gastric win
But Enhertu is coming.
Nuvalent presses ahead in ALK
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
